{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adalimumab+Placebo&page=4", "query": { "intervention": "Adalimumab Placebo", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 89, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adalimumab+Placebo&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adalimumab+Placebo&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T11:47:14.624Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00408629", "title": "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2006-11", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-05-03", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 36, "location_summary": "Anaheim, California • Wheat Ridge, Colorado • Hamden, Connecticut + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408629" }, { "nct_id": "NCT02808975", "title": "Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hidradenitis Suppurativa (HS)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 206, "start_date": "2016-07-18", "completion_date": "2019-10-16", "has_results": true, "last_update_posted_date": "2020-05-14", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 9, "location_summary": "Beverly Hills, California • Encino, California • Irvine, California + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02808975" }, { "nct_id": "NCT03217734", "title": "MAP Study: Methotrexate and Adalimumab in Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Jeffrey J Crowley MD", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2017-04-10", "completion_date": "2018-12-31", "has_results": false, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 4, "location_summary": "Bakersfield, California • Santa Monica, California • Rockville, Maryland + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03217734" }, { "nct_id": "NCT04655807", "title": "A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn Disease" ], "interventions": [ { "name": "JNJ-64304500", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2021-03-03", "completion_date": "2023-09-04", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04655807" }, { "nct_id": "NCT05814627", "title": "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Upadacitinib Matching Placebo", "type": "DRUG" }, { "name": "Adalimumab Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 487, "start_date": "2023-06-15", "completion_date": "2026-07-15", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 85, "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05814627" }, { "nct_id": "NCT00550446", "title": "A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "CP-690,550", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2007-09", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2013-01-03", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 22, "location_summary": "Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Northridge", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550446" }, { "nct_id": "NCT00348283", "title": "Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Crohn's Disease" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 135, "start_date": "2006-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2011-04-11", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Plymouth", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348283" }, { "nct_id": "NCT02760407", "title": "Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Olokizumab 64mg q4w", "type": "DRUG" }, { "name": "Olokizumab 64mg q2w", "type": "DRUG" }, { "name": "Adalimumab 40mg q2w", "type": "DRUG" }, { "name": "Placebo q2w", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm International, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1648, "start_date": "2016-06-06", "completion_date": "2019-11-05", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 64, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760407" }, { "nct_id": "NCT01893996", "title": "Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis", "Cardiovascular Disease" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonathan Graf", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2013-07", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2021-04-09", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01893996" }, { "nct_id": "NCT03259074", "title": "Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GP2017 (adalimumab biosimilar)", "type": "BIOLOGICAL" }, { "name": "AIN457 150 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 859, "start_date": "2017-11-30", "completion_date": "2021-11-29", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-07T11:47:14.624Z", "location_count": 19, "location_summary": "Mesa, Arizona • Escondido, California • La Mesa, California + 16 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03259074" } ] }